These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 15009836)
21. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Al-Akash SI; Al Makadma AS; Al Omari MG Pediatr Transplant; 2005 Apr; 9(2):249-53. PubMed ID: 15787802 [TBL] [Abstract][Full Text] [Related]
22. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Milani C; Castillo J Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725 [TBL] [Abstract][Full Text] [Related]
23. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402 [TBL] [Abstract][Full Text] [Related]
24. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. Zompi S; Tulliez M; Conti F; Leblond V; Gaulard P; Blanche P; Durand F; Ghandi D; Dreyfus F; Louvel A; Calmus Y; Bouscary D J Hepatol; 2000 Mar; 32(3):521-7. PubMed ID: 10735625 [TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab. Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811 [TBL] [Abstract][Full Text] [Related]
26. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Looney RJ Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522 [TBL] [Abstract][Full Text] [Related]
28. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Lee JJ; Lam MS; Rosenberg A Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421 [TBL] [Abstract][Full Text] [Related]
29. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Kazkaz H; Isenberg D Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135 [TBL] [Abstract][Full Text] [Related]
30. A case of post-transplant lymphoproliferative disease presenting as CD20-expressing, Epstein-Barr-virus positive Hodgkin lymphoma. Stern M; Herrmann R; Rochlitz C; Dirnhofer S; Pless M Eur J Haematol; 2005 Mar; 74(3):267-70. PubMed ID: 15693799 [TBL] [Abstract][Full Text] [Related]
31. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912 [TBL] [Abstract][Full Text] [Related]
32. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation. Kasow KA; Leung W; Horwitz EM; Woodard P; Handgretinger R; Hale GA Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900 [TBL] [Abstract][Full Text] [Related]
33. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets. Maloney DG Semin Oncol; 2005 Feb; 32(1 Suppl 1):S19-26. PubMed ID: 15786022 [TBL] [Abstract][Full Text] [Related]
34. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report. Latifzadeh SZ; Entezari V Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895 [TBL] [Abstract][Full Text] [Related]
35. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab. Markasz L; Vanherberghen B; Flaberg E; Otvös R; Stuber G; Gustafsson Jernberg A; Olah E; Skribek H; Szekely L Biomed Pharmacother; 2009 Jul; 63(6):413-20. PubMed ID: 18834693 [TBL] [Abstract][Full Text] [Related]
36. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Pfeiffer M; Stanojevic S; Feuchtinger T; Greil J; Handgretinger R; Barbin K; Jung G; Martin D; Niethammer D; Lang P Bone Marrow Transplant; 2005 Jul; 36(2):91-7. PubMed ID: 15908973 [TBL] [Abstract][Full Text] [Related]
37. Treatment of vascular rejection with rituximab in cardiac transplantation. Garrett HE; Duvall-Seaman D; Helsley B; Groshart K J Heart Lung Transplant; 2005 Sep; 24(9):1337-42. PubMed ID: 16143254 [TBL] [Abstract][Full Text] [Related]
38. Use of rituximab to decrease panel-reactive antibodies. Balfour IC; Fiore A; Graff RJ; Knutsen AP J Heart Lung Transplant; 2005 May; 24(5):628-30. PubMed ID: 15896765 [TBL] [Abstract][Full Text] [Related]
40. A review of the current use of rituximab in autoimmune diseases. Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]